David Gerber, MD


Clinical Pearls and the Future of LEMS

January 19th 2022

Experts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.

Case Review: Small Cell Lung Cancer Following LEMS

January 11th 2022

An oncologist reviews the case of a 57-year-old man diagnosed with small cell lung cancer after Lambert-Eaton myasthenic syndrome.

Monitoring Patients with SCLC and LEMS

January 11th 2022

Drs. Steven Vernino and David Gerber continue their conversation on their preferred treatment approaches and monitoring strategies for Lambert-Eaton myasthenic syndrome and small cell lung cancer.

Treatment Options for LEMS

January 4th 2022

Key opinion leaders detail the treatment options available for Lambert-Eaton myasthenic syndrome.

Front-line Treatment Options for SCLC

January 4th 2022

Steven Vernino, MD, describes the first-line treatment options for small cell lung cancer with Lambert-Eaton myasthenic syndrome.

LEMS Case Review

December 28th 2021

Drs. David Gerber and Steven Vernino review the case of a 64-year-old man with Lambert-Eaton myasthenic syndrome.

LEMS Diagnosis: Patient Presentation and Testing

December 28th 2021

Two experts debate the preferred testing options for Lambert-Eaton myasthenic syndrome presenting with small cell lung cancer.

Testing for LEMS

December 21st 2021

A neurologist explains how to test for and diagnose Lambert-Eaton myasthenic syndrome.

Defining LEMS

December 21st 2021

David Gerber, MD, and Steven Vernino, MD, PhD, provide an overview of Lambert-Eaton myasthenic syndrome and its association with cancers.

Dr. Gerber on the Rationale to Combine Immunotherapy With Radiation in Lung Cancer

October 2nd 2020

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.